Total Returns (Price + Dividend) 
Company does not have enough history
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.29%
EBIT Growth (5y)
-183.26%
EBIT to Interest (avg)
-0.86
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.90
Sales to Capital Employed (avg)
0.47
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.85
EV to EBIT
-2.90
EV to EBITDA
-2.91
EV to Capital Employed
5.39
EV to Sales
5.39
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-186.08%
ROE (Latest)
-110.36%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
Bearish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - May'25 - YoY
May'25
May'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.30
-0.30
Interest
0.00
0.00
Exceptional Items
0.10
0.00
Consolidate Net Profit
-0.30
0.00
Operating Profit Margin (Excl OI)
0.00%
-40,768.60%
4,076.86%
USD in Million.
Net Sales
YoY Growth in quarter ended May 2025 is 0.00% vs -100.00% in May 2024
Consolidated Net Profit
YoY Growth in quarter ended May 2025 is 0.00% vs 100.00% in May 2024
Annual Results Snapshot (Consolidated) - Feb'25
Feb'25
Feb'24
Change(%)
Net Sales
0.10
0.10
Operating Profit (PBDIT) excl Other Income
-1.80
-1.20
-50.00%
Interest
0.00
0.00
Exceptional Items
-0.10
0.00
Consolidate Net Profit
-1.90
-1.20
-58.33%
Operating Profit Margin (Excl OI)
-12,566.10%
-19,666.80%
710.07%
USD in Million.
Net Sales
YoY Growth in year ended Feb 2025 is 0.00% vs -66.67% in Feb 2024
Consolidated Net Profit
YoY Growth in year ended Feb 2025 is -58.33% vs 14.29% in Feb 2024
About The BC Bud Corp. 
The BC Bud Corp.
Pharmaceuticals & Biotechnology
Entheos Capital Corp. is a Canada-based company. The Company offers a range of financial and communications services to companies in various industry sectors. The Company provides business advisory services in connection with venture capital markets, investor relations, initial public offerings and secondary financings, mergers and acquisitions, public market administration, as well as media and marketing advice. The Company offer Business Advisory and Capital Markets services to a range of growth companies. The Company's Business Advisory platform offers a range of products and services designed for clients' exposure and visibility within a network of Investment Advisors in independent and bank-owned investment dealers.
Company Coordinates 
Company Details
Suite 2080-777 Hornby Street , VANCOUVER BC : V6Z 1S4
Registrar Details






